Medically reviewed by Drugs.com. Last updated on Mar 19, 2021.
Generic name: HUMAN IMMUNOGLOBULIN G 100mg in 1mL; HYALURONIDASE (HUMAN RECOMBINANT) 160[USP'U] in 1mL
Dosage form: subcutaneous injection
For subcutaneous use only.
Initiation of Treatment with HYQVIA
- For patients previously on another IgG treatment, administer the first dose approximately one week after the last infusion of their previous treatment.
- Increase the dose and frequency from a 1-week dose to a 3- or 4-week dose (see ramp-up schedule in Table 1).
- Initiating treatment at a full monthly dose was not evaluated in the clinical trial.
|Week||Infusion Number||Dose Interval||Example for 30 grams per 4 weeks|
|1||1st infusion||1-week-dose||7.5 grams|
|2||2nd infusion||2-week-dose||15 grams|
|4||3rd infusion||3-week-dose||22.5 grams|
|7||4th infusion (if required)||4-week-dose||30 grams|
For patients switching from Immune Globulin Intravenous (Human) [IGIV] treatment:
- Administer HYQVIA at the same dose and frequency as the previous intravenous treatment, after the initial dose ramp-up.
For patients at risk for measles exposure:
- If a patient has been exposed to measles, it may be prudent to administer a dose of HYQVIA as soon as possible and within 6 days of exposure. A dose of 400 mg/kg should provide a serum level > 240 mIU/mL of measles antibodies for at least two weeks.
- If a patient is at risk of future measles exposure and receives a dose of less than 530 mg/kg every 3 to 4 weeks, the dose should be increased to at least 530 mg/kg. This should provide a serum level of 240 mIU/mL of measles antibodies for at least 22 days after infusion.
Individualization of Dose
- If HYQVIA is administered at the same dose and frequency, the serum IgG levels from HYQVIA should be comparable to serum IgG levels from intravenous treatment.
For dose adjustment:
- Calculate the difference between the patient's serum IgG trough level during HYQVIA treatment and the IgG trough level during the previous intravenous treatment.
- Find this difference (in mg/dL) in the columns of Table 2 and the corresponding amount (in mL) by which to increase or decrease the dose based on the patient's body weight and desired change in IgG trough level.
|Body Weight||100 mg/dL||200 mg/dL||300 mg/dL||400 mg/dL|
|10 kg||3 mL||6 mL||9 mL||12 mL|
|20 kg||6 mL||12 mL||18 mL||24 mL|
|30 kg||9 mL||18 mL||27 mL||36 mL|
|40 kg||12 mL||24 mL||36 mL||48 mL|
|50 kg||15 mL||30 mL||45 mL||61 mL|
|60 kg||18 mL||36 mL||55 mL||73 mL|
|70 kg||21 mL||42 mL||64 mL||85 mL|
|80 kg||24 mL||48 mL||73 mL||97 mL|
|90 kg||27 mL||55 mL||82 mL||109 mL|
|100 kg||30 mL||61 mL||91 mL||121 mL|
|110 kg||33 mL||67 mL||100 mL||133 mL|
|120 kg||36 mL||73 mL||109 mL||145 mL|
|130 kg||39 mL||79 mL||118 mL||158 mL|
|140 kg||42 mL||85 mL||127 mL||170 mL|
Example 1: A patient with a body weight of 80 kg has a measured IgG trough level of 800 mg/dL and the reference trough level is 1000 mg/dL. The trough level difference is 200 mg/dL (1000 mg/dL minus 800 mg/dL). The dose of HYQVIA would be increased by 48 mL (4.8 grams) per dosing interval.
Example 2: A patient with a body weight of 60 kg has a measured IgG trough level of 1000 mg/dL and the reference trough level is 900 mg/dL. The trough level difference is -100 mg/dL (900 mg/dL minus 1000 mg/dL). The dose of HYQVIA would be decreased by 18 mL (1.8 grams) per dosing interval.
HYQVIA can be used to administer a full therapeutic dose in one site up to every four weeks. Adjust the frequency and number of infusion sites taking into consideration volume, total infusion time, and tolerability. Adjust the frequency as needed so that the patient receives the same weekly equivalent dose.
Example 3: When adjusting a dose of 30 grams administered every 3 weeks, administer 40 grams of HYQVIA every 4 weeks. If a higher trough level is required relative to intravenous treatment at 3- or 4-week intervals, increase the dose or decrease the dosing interval. Evaluate the use of a second site or infusing at shorter intervals when the volume of HYQVIA is greater than 600 mL.
If a patient misses a dose, administer the missed dose as soon as possible and then resume scheduled treatments as applicable.
If HYQVIA is administered at a different interval than the previous treatment, either intravenously or subcutaneously, then Table 2 should not be used and the dose of HYQVIA should be adjusted, if necessary, based on clinical response.
HYQVIA should be administered by a healthcare professional, caregiver or self-administered by the patient after appropriate training.
- Infusion of Immune Globulin Infusion 10% (Human) requires an infusion pump capable of infusing a patient's therapeutic dose at infusion rates up to 300 mL/hr/site. The pump must have the ability to titrate the flow rate up or down if required to improve tolerability. To ensure maximum flow rates, use a subcutaneous needle set that is 24 gauge and labeled for high flow rates.
- Infusion site leakage can occur during or after subcutaneous administration of immunoglobulin, including HYQVIA. Consider using longer needles (14 or 12 mm rather than 9 mm) and/or more than one infusion site.
- Infuse the two components of HYQVIA sequentially, beginning with the Recombinant Human Hyaluronidase.
- Initiate infusion of the full dose of the Immune Globulin Infusion 10% (Human) through the same subcutaneous needle set within approximately 10 minutes of the Recombinant Human Hyaluronidase infusion. For each full or partial vial of Immune Globulin Infusion 10% (Human) used, administer the entire contents of the Recombinant Human Hyaluronidase vial.
Selection of Infusion Site(s)
The suggested site(s) for the infusion of HYQVIA are the abdomen and thighs. If two sites are used, the two infusion sites should be on opposite sides of the body. Avoid bony prominences, or areas that are scarred, inflamed, or infected.
Volume per Site
Administer up to 600 mL per site for patients whose body weight is greater than or equal to 40 kg and up to 300 mL per site for patients whose body weight is less than 40 kg.
A second site can be used at the discretion of the physician and patient based on tolerability and total volume. If a second site is used, administer half the total volume of Recombinant Human Hyaluronidase of HYQVIA in each site.
Rate of Infusion
Administer the Recombinant Human Hyaluronidase of HYQVIA at an initial rate per site of approximately 1 to 2 mL per minute, or as tolerated.
Administer Immune Globulin Infusion 10% (Human) of HYQVIA at rates as shown in Table 3 for the initial infusions. If the patient tolerates these infusions at the full dose and maximum rate, adjust both the time intervals and number of rate changes of the ramp-up used for successive infusions at the discretion of the physician and patient.
|First 2 Infusions||Subsequent 2 or 3 Infusions|
|Subjects < 40 kg
|Subjects ≥ 40 kg
|Subjects < 40 kg
|Subjects ≥ 40 kg
|Intervals||Rate per site||Rate per site||Rate per site||Rate per site|
|Minutes||mL per hour||mL per hour||mL per hour||mL per hour|
|5 - 15||5||10||10||10|
|5 - 15||10||30||20||30|
|5 - 15||20||60||40||120|
|5 - 15||40||120||80||240|
|Remainder of infusion||80||240||160||300|
Preparation and Handling
- Visually inspect both vials of HYQVIA for discoloration and particulate matter prior to administration.
- The appearance of the Immune Globulin Infusion 10% (Human) of HYQVIA can vary from clear or slightly opalescent and colorless or pale yellow.
- The appearance of the Recombinant Human Hyaluronidase of HYQVIA should be clear and colorless.
- Do not use either component of HYQVIA if either solution is cloudy or has particulates.
- Allow refrigerated product to come to room temperature before use. Do not apply heat or place in microwave.
- Do not shake HYQVIA.
- Do not mix the Recombinant Human Hyaluronidase and the Immune Globulin Infusion 10% (Human) of HYQVIA into the same container prior to administration.
- Do not mix or administer components of HYQVIA with other products. Administer components of HYQVIA sequentially. Do not use either component alone.
- Flush the infusion line with normal saline or Dextrose 5% in water (D5W) if required.
- HYQVIA contains no preservative. Discard any unused product according to local standards for biohazard products.
Instructions for Administration
Use aseptic technique when preparing and administering HYQVIA for infusion.
For more detail on steps, see accompanying Information for Patients.
1. Inspect the vials: Inspect for clarity, color, and expiration date(s)
2. Prepare for infusion:
- Gather supplies: HYQVIA dual vial unit(s), ancillary supplies, sharps container and infusion pump (program pump per physician recommendation following manufacturer's instructions).
- Prepare a clean work area.
- Wash hands.
- If the Immune Globulin Infusion 10% (Human) and Recombinant Human Hyaluronidase are pooled into separate containers, skip to Step 5.
3. Prepare the Recombinant Human Hyaluronidase of HYQVIA (Labeled as "HY"):
- Remove the purple protective cap and ensure the blue vial caps are removed.
- Wipe each stopper with a sterile alcohol wipe and allow to dry.
- Attach a syringe to a needle/needle-less transfer device. A sterile needle or needle-less transfer device [(18-22) gauge sterile needle] may be used for all vial sizes. Position the sharp tip of the needle/needle-less transfer device over the center of the vial stopper and insert it at a 90-degree angle. Inject air and then draw the full contents of each vial labeled "HY" into a single syringe, if possible.
- Attach the syringe containing the Recombinant Human Hyaluronidase to the subcutaneous needle set and prime up to the needle hub.
4. Prepare Immune Globulin Infusion 10% (Human) of HYQVIA (Labeled as "IG"):
- Wipe each stopper with a sterile alcohol wipe and allow to dry.
- Transfer the vial(s) labeled "IG" using one of the following methods:
- Pool into an infusion bag, using a transfer device per manufacturer's directions. Attach and prime the pump administrating tubing; or
- Directly spike the vial using a vented pump administration tubing and prime as directed.
If using a syringe driver, transfer into the syringe(s), preferably using a vented spike.
5. Prepare the infusion site(s):
- Potential sites for infusion include the middle to upper abdomen and thigh.
- Avoid: bony prominences, blood vessels, scars, or areas that are inflamed or infected.
- If two sites are desired, a bifurcated needle set may be used on opposite sides of the body.
- Rotate sites by choosing opposite sides of the body between successive infusions.
- Cleanse the infusion site(s) with a sterile alcohol wipe beginning at the center of each infusion site and moving outward in a circular motion. Allow the infusion site(s) to dry.
6. Insert and secure the 24-gauge subcutaneous needle:
- Pinch at least one inch of skin between two fingers. Insert the needle at a 90-degree angle into the subcutaneous tissue and secure the needle with sterile tape.
- Check placement: gently pull back on the plunger of the attached syringe and monitor for any blood return in the tubing.
- If blood is seen in the tubing, remove and discard the needle and repeat steps 3, 5 and 6 with a new subcutaneous needle and infusion site.
- Secure the needle in place with a sterile protective dressing.
7. Administer the Recombinant Human Hyaluronidase of HYQVIA:
Infuse the Recombinant Human Hyaluronidase manually at an initial rate of approximately 1 to 2 mL per minute per infusion site and increase as tolerated. If more than one site is used, divide the contents equally between sites. At the end of infusion, disconnect the empty syringe and attach the pump tubing/syringe containing the Immune Globulin Infusion 10% (Human) of HYQVIA to the same subcutaneous needle set.
8. Administer the Immune Globulin Infusion 10% (Human) of HYQVIA:
Within approximately 10 minutes of completing the infusion of the Recombinant Human Hyaluronidase of HYQVIA, start the variable rate program of the infusion pump to initiate the infusion of the full therapeutic dose of Immune Globulin Infusion 10% (Human) of HYQVIA. At the end of infusion, flush the infusion tubing up to the needle with normal saline or Dextrose 5% in water (D5W), if required.
9. Remove subcutaneous needle(s) from the infusion site(s):
After the infusion is complete, remove the needle set and cover with a protective dressing. Discard any partially used vial(s) and disposable supplies in accordance with local requirements.
10. Document the infusion:
Remove the peel-off label from each Immune Globulin Infusion 10% (Human) vial of HYQVIA used and affix to the patient's treatment record or infusion log. In addition, record the time, date, dose, infusion site location and any reactions after each infusion.
For self-administration, provide the patient with instructions and training for infusion in the home or other appropriate setting.
More about Hyqvia (hyaluronidase / immune globulin)
- Side Effects
- During Pregnancy
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: immune globulins
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.